- Home
- NMRK vs QURE Comparison
NMRK vs QURE Comparison
Compare NMRK & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NMRK | QURE |
|---|---|---|
| Founded | 1929 | 1998 |
| Country | United States | Netherlands |
| Employees | N/A | 248 |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 3.1B |
| IPO Year | 2017 | 2013 |
Fundamental Metrics
Financial Performance| Metric | NMRK | QURE |
|---|---|---|
| Price | $12.57 | $23.17 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 12 |
| Target Price | $19.75 | ★ $66.91 |
| AVG Volume (30 Days) | 1.6M | ★ 2.2M |
| Earning Date | 10-29-2026 | 11-09-2026 |
| Dividend Yield | ★ 1.91% | N/A |
| EPS Growth | ★ 100.00 | 29.67 |
| EPS | ★ 0.18 | N/A |
| Revenue | ★ $3,294,024,000.00 | $13,107,000.00 |
| Revenue This Year | $16.62 | $56.20 |
| Revenue Next Year | $9.24 | $357.08 |
| P/E Ratio | $69.92 | ★ N/A |
| Revenue Growth | ★ 20.29 | N/A |
| 52 Week Low | $12.18 | $8.73 |
| 52 Week High | $19.84 | $71.50 |
Technical Indicators
Market Signals| Indicator | NMRK | QURE |
|---|---|---|
| Relative Strength Index (RSI) | 31.63 | 18.12 |
| Support Level | N/A | $21.91 |
| Resistance Level | $16.13 | $27.66 |
| Average True Range (ATR) | 0.45 | 2.20 |
| MACD | -0.07 | -2.22 |
| Stochastic Oscillator | 17.85 | 8.29 |
Price Performance
Historical ComparisonAbout NMRK Newmark Group Inc.
Newmark Group Inc is a commercial real estate advisory firm. It offers services, including leasing and corporate advisory services, investment sales, commercial mortgage brokerage, appraisal and valuation, project management, and property, among others. Newmark offers a diverse array of integrated services and products designed to meet the full needs of both real estate investors/owners and occupiers. The company provides real estate strategic consulting and systems integration services to CFI's clients including many Fortune and Forbes companies, owner-occupiers, government agencies, healthcare, and higher education clients.
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.